LONDON (dpa-AFX) - Propeller Health announced U.S. FDA 510(k) clearance to market its Propeller platform for use with GSK's Ellipta inhaler, a dry powder inhaler. The sensor for the Ellipta inhaler was built and cleared as part of a development agreement and R&D collaboration between Propeller and GSK. The FDA clearance follows CE Mark and Health Canada registration for the device and system earlier in the year.
The Propeller Health platform has been used by patients with asthma or COPD in over 45 commercial programs across the US, including major healthcare systems, payers, employers and other commercial partners.
Copyright RTT News/dpa-AFX
Jetzt für 0€ handeln - auf Smartbroker.de